Last updated: June 1, 2026
Orfadin (nitisinone) suppliers: Who manufactures and supplies Orfadin in the US and key markets?
Orfadin is the brand name for nitisinone (for hereditary tyrosinemia type 1). The supplier landscape is dominated by the originator’s commercial manufacturer(s) for the drug product, plus a set of API (nitisinone) suppliers that provide active ingredient to branded and generic manufacturers.
Who supplies Orfadin (nitisinone) API and drug product today?
Featured answer: Orfadin supply typically consists of:
- API suppliers producing nitisinone (often under contract manufacturing or tolling arrangements).
- Drug product manufacturers producing Orfadin tablets (packaged product for commercial sale).
- Secondary logistics/wholesaler networks distributing to pharmacy and hospital channels.
What matters for sourcing decisions
- Regulatory status alignment: API and drug substance must support registration/DMF references used in finished-product filings.
- Quality system compatibility: tablet performance (uniformity, dissolution, impurity profiles) is sensitive to API grade and crystallinity.
- Supply continuity risk: nitisinone is a niche API with concentrated commercial demand.
Orfadin formulation and strength that drive supply
- Orfadin is sold as oral tablets in commercial strengths (commonly including 2 mg and 5 mg for hereditary tyrosinemia type 1 treatment in labeled practice).
Key buyer-side diligence questions suppliers must clear
- Control strategy for impurities (including process-related impurities)
- Analytical method transfer readiness (finished product release and stability)
- Traceability for starting materials used in nitisinone synthesis routes
- Ability to support DMF/CEP documentation needs
Which companies manufacture Orfadin tablets under contract?
Featured answer: The Orfadin supply chain typically includes a commercial sponsor/brand owner and one or more contract manufacturers for tablet production and packaging.
How to map manufacturers in practice
- Identify the US FDA label “Manufactured for” and “Distributed by” entities for Orfadin.
- Cross-check with:
- Drug product section manufacturing site(s) listed in regulatory submissions
- Public CGMP inspection history of the tablet site(s)
- Country-specific SmPC/EPAR manufacturing statements (for non-US markets)
Which companies are the main Orfadin (nitisinone) API suppliers?
Featured answer: Nitisinone API supply is generally concentrated among:
- API producers that can meet pharmacopeial/registration impurity specifications, and
- Contract or toll manufacturers supporting DMF-referenced supply to multiple finished-product makers.
API sourcing considerations
- Chemical synthesis route control (impurity profile consistency)
- Solid-state quality control (particle size distribution, polymorph control)
- Stability handling for nitisinone API storage and shipment
What is the Orange Book status of Orfadin and how does it affect supplier eligibility?
Featured answer: Orfadin is protected by a mix of drug substance, formulation, and method-of-use patent coverage depending on jurisdiction. That affects the number of legally cleared finished-product suppliers and the ability of generics to enter without patent carve-outs or settlements.
Why this matters to sourcing
- When exclusivity/patents are active, only the brand or authorized licensees typically supply.
- Post-expiry, additional manufacturers may appear, but product quality and labeling comparability remain gating items.
Are generic nitisinone or authorized biologic-equivalent versions available as Orfadin substitutes?
Featured answer: For Orfadin, the substitution pathway is typically generic nitisinone tablets rather than a biosimilar route (nitisinone is a small molecule).
Supply impact
- Once generics enter, buyer leverage usually shifts toward:
- price competitiveness
- manufacturing capacity
- consistent impurity profiles and dissolution performance
Which suppliers are relevant for US, EU, and other regulated markets?
Featured answer: Supplier names differ by geography because drug product manufacturing and distribution can be split among:
- US commercial supply chains tied to US labeling and distribution,
- EU/UK supply chains tied to national marketing authorization manufacturing statements,
- other markets where local importers and wholesalers distribute Orfadin.
Regulatory alignment you need for multi-country procurement
- Whether the drug product is marketed under:
- EU centralized marketing authorization vs national licensing
- local label variations that can require country-specific stability and packaging
- Whether the importer holds licenses for controlled cold-chain or special handling (if applicable to the local product form)
What drives Orfadin supply constraints and supplier risk?
Featured answer: The biggest supply constraints in specialty small-molecule brands like Orfadin usually come from:
- concentrated API manufacturing capacity
- limited qualified second-source API providers
- regulatory and quality requalification overhead for new manufacturing sites
Supply chain risk indicators
- API vendor single-site dependence
- recent DMF updates that coincide with production scale-ups
- changes in tablet manufacturer or packaging site
- shortages reported through national shortage databases (where applicable)
How to shortlist Orfadin suppliers for procurement and contracting
Featured answer: A procurement shortlist should be built from supplier capability data tied to regulatory and batch performance.
Contracting checklist
- Confirm finished product manufacturer site(s) and responsibilities
- Confirm API sourcing and DMF/CEP linkage where required
- Demand batch release data packages for:
- assay
- impurities
- dissolution
- stability pull (accelerated and real-time)
- Validate packaging configuration against local label requirements
- Include change-control clauses for API synthesis route or polymorph controls
Key Takeaways
- Orfadin supply is structured around nitisinone API producers plus tablet drug product manufacturers and packagers tied to the branded regulatory dossier.
- Supplier qualification depends on regulatory dossier linkage, impurity control, and solid-state consistency for nitisinone.
- Supply continuity risk is usually driven by API capacity concentration and the cost/time to requalify additional manufacturing sites.
- Multi-market sourcing requires aligning labeling, manufacturing sites, and distribution licensing by jurisdiction.
FAQs
- What are the typical Orfadin tablet strengths and how do they affect supplier capacity?
- How can procurement teams verify the API source for Orfadin without relying on marketing claims?
- Do Orfadin shortages correlate more with API supply or tablet manufacturing capacity?
- What quality attributes are most critical for nitisinone API used in Orfadin tablets?
- Which documentation best supports regulatory submissions when switching Orfadin suppliers?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-01).
- FDA. Drugs@FDA: Orfadin (nitisinone) label information. (Accessed 2026-06-01).
- European Medicines Agency. EPAR/SmPC documentation for Orfadin (nitisinone). (Accessed 2026-06-01).
